Breaking News

TxCell Signs Strategic Agreement with MaSTherCell

Belgian CMO will manufacture TxCell’s European cell therapy products

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TxCell SA, a biotechnology company developing personalized cell immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, has signed a 5-year agreement with MaSTherCell, a contract manufacturing organization (CMO) based in Belgium. MaSTherCell will be the exclusive manufacturer in Europe of all products from TxCell’s ASTrIA platform. TxCell previously appointed MaSTherCell in July 2015 for the manufacturing of TxCell’s lead product Ovasave for t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters